Antoine Beurton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antoine Beurton has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Ouattara
CHU Bordeaux, Department of Anaesthesia and Critical Care, Magellan Medico-Surgical Centre, Bordeaux, France
7 shared publications Julien Imbault
Department of Cardiovascular Anaesthesia and Critical Care, CHU Bordeaux, Bordeaux, Pessac, France
7 shared publications- Thomas Modine
CHU Bordeaux, Bordeaux, France
5 shared publications Alexandre Ouattara
Department of Cardiovascular Anaesthesia and Critical Care, CHU Bordeaux, Bordeaux, Pessac, France
4 shared publicationsFrançois-Xavier Hérion
Department of Cardiovascular Anesthesia and Critical Care, CHU Bordeaux, Bordeaux, France; University of Bordeaux, INSERM, BMC, Pessac, France
4 shared publications- Julien Ternacle
Unité Médico-Chirurgicale des Valvulopathies Hôpital Cardiologique Haut-Lévêque, CHU de Bordeaux , Avenue Magellan, 33600, Pessac
4 shared publications
Latest Publications
- 21 October 2026
- Published by SAGE Publications in Perfusion
Lunar phases, meteorological conditions, astrological signs, and postoperative outcomes of acute type A aortic dissection: Results of a retrospective cohort study
Background: Acute type A aortic dissection (ATAAD) is a surgical emergency associated with high mortality. While patient-related risk factors are well-established, beliefs persist regarding the influence of lunar phases, meteorological conditions, and astrological signs on disease occurrence and outcomes. Methods: We retrospectively analysed all patients who underwent emergency surgery for ATAAD at Bordeaux University Hospital between 1996 and 2020. The primary objective was to assess the association between environmental factors (lunar phases, atmospheric pressure, temperature, and astrological signs) and ATAAD incidence. Secondary objectives included assessing their association with 30-day mortality and postoperative morbidity (intensive care unit length of stay, extracorporeal membrane oxygenation use, and mesenteric infarction). Meteorological data were available for 603 patients from 2010 onward. Results: Among 920 patients (70% male; mean age 63 ± 13 years), the 30-day mortality rate was 9.7%. Lunar phases were not associated with ATAAD incidence (first quarter 26%, last quarter 25%, new moon 25%, full moon 24%; p = 0.91), mortality, or complications. Atmospheric pressure showed no association with ATAAD occurrence or outcomes. Temperature showed a weak correlation with ATAAD incidence (r = 0.11, p = 0.01), but not with mortality. Astrological signs were not associated with ATAAD incidence, mortality, or morbidity. Longer cardiopulmonary bypass duration (odds ratio [OR] = 0.994 per minute; p = 0.01) and diabetes (OR = 4.63; p = 0.01) were associated with 30-day mortality. Conclusions: Environmental factors were not associated with ATAAD incidence or outcomes. Established clinical factors remain the primary determinants of mortality.
- 21 October 2026
- Published by SAGE Publications in Perfusion
Lunar phases, meteorological conditions, astrological signs, and postoperative outcomes of acute type A aortic dissection: Results of a retrospective cohort study
Background: Acute type A aortic dissection (ATAAD) is a surgical emergency associated with high mortality. While patient-related risk factors are well-established, beliefs persist regarding the influence of lunar phases, meteorological conditions, and astrological signs on disease occurrence and outcomes. Methods: We retrospectively analysed all patients who underwent emergency surgery for ATAAD at Bordeaux University Hospital between 1996 and 2020. The primary objective was to assess the association between environmental factors (lunar phases, atmospheric pressure, temperature, and astrological signs) and ATAAD incidence. Secondary objectives included assessing their association with 30-day mortality and postoperative morbidity (intensive care unit length of stay, extracorporeal membrane oxygenation use, and mesenteric infarction). Meteorological data were available for 603 patients from 2010 onward. Results: Among 920 patients (70% male; mean age 63 ± 13 years), the 30-day mortality rate was 9.7%. Lunar phases were not associated with ATAAD incidence (first quarter 26%, last quarter 25%, new moon 25%, full moon 24%; p = 0.91), mortality, or complications. Atmospheric pressure showed no association with ATAAD occurrence or outcomes. Temperature showed a weak correlation with ATAAD incidence (r = 0.11, p = 0.01), but not with mortality. Astrological signs were not associated with ATAAD incidence, mortality, or morbidity. Longer cardiopulmonary bypass duration (odds ratio [OR] = 0.994 per minute; p = 0.01) and diabetes (OR = 4.63; p = 0.01) were associated with 30-day mortality. Conclusions: Environmental factors were not associated with ATAAD incidence or outcomes. Established clinical factors remain the primary determinants of mortality.
- 9 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (10) , 1873-1884
Imaging REASSESSment of embolic events before antibiotic discontinuation in infective endocarditis: REASSESS-IE study
Introduction: Embolic events (EEs) in infective endocarditis (IE) are frequent and associated with poor prognosis. Follow-up imaging is not standardized despite the risk of persistent extracardiac foci. We aimed to assess the therapeutic impact of imaging reassessment before antibiotic discontinuation. Methods and results: Prospective multicentre study including patients with definite or possible IE complicated by EEs (2013–2022). Asymptomatic or clinically stable patients who underwent follow-up imaging before antibiotic discontinuation to reassess IE–related EEs were included, whereas those imaged for clinical reasons were excluded. The primary endpoint was therapeutic impact: antibiotic modification and/or intervention. Secondary endpoints included all-cause mortality. Overall, 54% (n = 700/1300) of the entire cohort had IE-related EEs. Among them, 554 patients (mean age 65.7 years, 76% male) under antibiotic therapy were included: 49% with cerebral and 79% with extracerebral EEs, mainly ischaemic stroke (42%) and splenic embolism (40%). Follow-up imaging before antibiotic discontinuation (median, 6 weeks) was performed in 51% (n = 281/554), leading treatment modification in 5.7% (16/281), mainly in patients with Staphylococcus aureus IE complicated by abscess. In-hospital and 5-year mortality were 9.4% and 30.8%, respectively. Haemodynamic instability and comorbidities were associated with long-term mortality, whereas only cardiac surgery was associated with improved survival. Conclusion: Imaging reassessment of IE-related EEs before stopping antibiotics may lead to therapeutic modification in asymptomatic or clinically stable patients using a risk-stratified individualized imaging strategy guided by the endocarditis teams, rather than a uniform approach. Prospective studies are needed to define standardized imaging algorithms.
- 9 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 27 (10) , 1873-1884
Imaging REASSESSment of embolic events before antibiotic discontinuation in infective endocarditis: REASSESS-IE study
Introduction: Embolic events (EEs) in infective endocarditis (IE) are frequent and associated with poor prognosis. Follow-up imaging is not standardized despite the risk of persistent extracardiac foci. We aimed to assess the therapeutic impact of imaging reassessment before antibiotic discontinuation. Methods and results: Prospective multicentre study including patients with definite or possible IE complicated by EEs (2013–2022). Asymptomatic or clinically stable patients who underwent follow-up imaging before antibiotic discontinuation to reassess IE–related EEs were included, whereas those imaged for clinical reasons were excluded. The primary endpoint was therapeutic impact: antibiotic modification and/or intervention. Secondary endpoints included all-cause mortality. Overall, 54% (n = 700/1300) of the entire cohort had IE-related EEs. Among them, 554 patients (mean age 65.7 years, 76% male) under antibiotic therapy were included: 49% with cerebral and 79% with extracerebral EEs, mainly ischaemic stroke (42%) and splenic embolism (40%). Follow-up imaging before antibiotic discontinuation (median, 6 weeks) was performed in 51% (n = 281/554), leading treatment modification in 5.7% (16/281), mainly in patients with Staphylococcus aureus IE complicated by abscess. In-hospital and 5-year mortality were 9.4% and 30.8%, respectively. Haemodynamic instability and comorbidities were associated with long-term mortality, whereas only cardiac surgery was associated with improved survival. Conclusion: Imaging reassessment of IE-related EEs before stopping antibiotics may lead to therapeutic modification in asymptomatic or clinically stable patients using a risk-stratified individualized imaging strategy guided by the endocarditis teams, rather than a uniform approach. Prospective studies are needed to define standardized imaging algorithms.
- Open Access
- 24 June 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (25) , 108783
Protected Mitral TEER With Temporary Ventricular Circulatory Support in Severe Left Ventricular Dysfunction for Heart Failure Management
- 24 June 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (25) , 108783
Open AccessProtected Mitral TEER With Temporary Ventricular Circulatory Support in Severe Left Ventricular Dysfunction for Heart Failure Management
- 24 April 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (4) , e271792
Fulminant recurrent myocarditis complicated by papillary muscle rupture and cardiogenic shock managed with ExtraCorporeal membrane oxygenation and impella support
We present a case of acute-on-recurrent viral myocarditis complicated by papillary muscle rupture of the mitral valve. This rare clinical scenario, combining refractory cardiogenic shock with acute severe mitral valve regurgitation, illustrates the therapeutic challenges associated with temporary mechanical circulatory support (tMCS). Although mitral valve replacement would theoretically correct the mechanical complication, cardiac surgery in the setting of profound cardiogenic and septic shock carries a high risk of failure. In this context, the combination of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) with left ventricular unloading using a micro-axial pump (Impella 5.5, Abiomed, USA) appeared to us to be the most appropriate strategy, offering time for stabilisation before surgical intervention. Despite intensive support and targeted immunomodulatory treatment, the patient presented with severe neurological injury, ultimately leading to withdrawal of life-sustaining therapies.
- 24 April 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (4) , e271792
Fulminant recurrent myocarditis complicated by papillary muscle rupture and cardiogenic shock managed with ExtraCorporeal membrane oxygenation and impella support
We present a case of acute-on-recurrent viral myocarditis complicated by papillary muscle rupture of the mitral valve. This rare clinical scenario, combining refractory cardiogenic shock with acute severe mitral valve regurgitation, illustrates the therapeutic challenges associated with temporary mechanical circulatory support (tMCS). Although mitral valve replacement would theoretically correct the mechanical complication, cardiac surgery in the setting of profound cardiogenic and septic shock carries a high risk of failure. In this context, the combination of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) with left ventricular unloading using a micro-axial pump (Impella 5.5, Abiomed, USA) appeared to us to be the most appropriate strategy, offering time for stabilisation before surgical intervention. Despite intensive support and targeted immunomodulatory treatment, the patient presented with severe neurological injury, ultimately leading to withdrawal of life-sustaining therapies.
- Open Access
Centrifugation versus filtration-based cell salvage: impact on perioperative bleeding in cardiac surgery—the COLTRANE randomised clinical trial – study protocol
Introduction Cardiac surgery remains a high-risk procedure for bleeding despite advances in patient blood management. Conventional centrifugation-based autotransfusion devices primarily recover red blood cells, losing platelets and coagulation factors. The SAME autotransfusion device (i-SEP, Nantes, France) introduces an innovative filtration-based approach, recovering erythrocytes, leucocytes and platelets to enhance perioperative haemostasis. The main objective is to determine whether the filtration-based SAME device reduces significant perioperative bleeding compared with the centrifugation-based system in high-risk cardiac surgery patients. Methods and analysis The Centrifugation-based vs filtration-based intraOperative cell saLvage on qualiTy of peRioperAtive haemostasis iN cardiac surgEry (COLTRANE) trial is a multicentre, parallel-group, single-blinded, superiority-randomised clinical trial. Conducted over 19 months in 10 French hospitals, the study will target patients at high risk of bleeding undergoing on-pump cardiac surgery via sternotomy. A total of 570 patients (285 per group) are required to achieve 80% statistical power for detecting clinically significant differences. Eligible patients will be randomised to either a centrifugation-based or filtration-based autotransfusion group. Both groups will follow standardised perioperative and cardiopulmonary bypass management, with the devices used only intraoperatively. The primary outcome is the proportion of patients with clinically significant perioperative bleeding defined as classes 2 to 4 of the Universal Definition of Perioperative Bleeding. The secondary outcomes include device efficiency and safety, perioperative haemostasis, lengths of intensive care unit and hospital stays, early postoperative morbidity and 30-day all-cause mortality. Ancillary studies will be performed to evaluate cell recovery and washing performance, the viscoelastic properties of retransfused blood (Quantra Qplus; Stago, Asnières-sur-Seine, France), and the effect of salvaged leucocytes on postoperative inflammation and immune function. Ethics and dissemination This trial has received a favourable opinion from the Committee for the Protection of Persons and authorisation from the French authorities (Comité de protection des personnes Nord Ouest, IDRCB: 2023-A02566-39). Protocol V.1.1 was approved on 22 January 2024. The trial is registered on ClinicalTrials.gov (NCT06425614). The findings will be disseminated through oral communications at national and international scientific meetings and peer-reviewed journal publications. Individual participant data will be made available on reasonable request to qualified researchers, following review and approval by the study sponsor and ethics committee. Trial registration number ClinicalTrials.gov, NCT06425614.
Open AccessCentrifugation versus filtration-based cell salvage: impact on perioperative bleeding in cardiac surgery—the COLTRANE randomised clinical trial – study protocol
Introduction Cardiac surgery remains a high-risk procedure for bleeding despite advances in patient blood management. Conventional centrifugation-based autotransfusion devices primarily recover red blood cells, losing platelets and coagulation factors. The SAME autotransfusion device (i-SEP, Nantes, France) introduces an innovative filtration-based approach, recovering erythrocytes, leucocytes and platelets to enhance perioperative haemostasis. The main objective is to determine whether the filtration-based SAME device reduces significant perioperative bleeding compared with the centrifugation-based system in high-risk cardiac surgery patients. Methods and analysis The Centrifugation-based vs filtration-based intraOperative cell saLvage on qualiTy of peRioperAtive haemostasis iN cardiac surgEry (COLTRANE) trial is a multicentre, parallel-group, single-blinded, superiority-randomised clinical trial. Conducted over 19 months in 10 French hospitals, the study will target patients at high risk of bleeding undergoing on-pump cardiac surgery via sternotomy. A total of 570 patients (285 per group) are required to achieve 80% statistical power for detecting clinically significant differences. Eligible patients will be randomised to either a centrifugation-based or filtration-based autotransfusion group. Both groups will follow standardised perioperative and cardiopulmonary bypass management, with the devices used only intraoperatively. The primary outcome is the proportion of patients with clinically significant perioperative bleeding defined as classes 2 to 4 of the Universal Definition of Perioperative Bleeding. The secondary outcomes include device efficiency and safety, perioperative haemostasis, lengths of intensive care unit and hospital stays, early postoperative morbidity and 30-day all-cause mortality. Ancillary studies will be performed to evaluate cell recovery and washing performance, the viscoelastic properties of retransfused blood (Quantra Qplus; Stago, Asnières-sur-Seine, France), and the effect of salvaged leucocytes on postoperative inflammation and immune function. Ethics and dissemination This trial has received a favourable opinion from the Committee for the Protection of Persons and authorisation from the French authorities (Comité de protection des personnes Nord Ouest, IDRCB: 2023-A02566-39). Protocol V.1.1 was approved on 22 January 2024. The trial is registered on ClinicalTrials.gov (NCT06425614). The findings will be disseminated through oral communications at national and international scientific meetings and peer-reviewed journal publications. Individual participant data will be made available on reasonable request to qualified researchers, following review and approval by the study sponsor and ethics committee. Trial registration number ClinicalTrials.gov, NCT06425614.
- 27 June 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (16) , 2049-2051
All-in-One Percutaneous Approach to Treat Mitral Annuloplasty Dysfunction, Aortic Regurgitation, and Aortic Root Pseudoaneurysm
- 27 June 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (16) , 2049-2051
All-in-One Percutaneous Approach to Treat Mitral Annuloplasty Dysfunction, Aortic Regurgitation, and Aortic Root Pseudoaneurysm
- 29 April 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (3) , 107526
Antimicrobial suppressive therapy in prosthetic valve endocarditis rejected from surgery despite indication
- 29 April 2025
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (3) , 107526
Antimicrobial suppressive therapy in prosthetic valve endocarditis rejected from surgery despite indication
- 11 September 2024
- Published by SAGE Publications in Perfusion
- Vol. 40 (5) , 1297-1298
Letter re: Comments on the article “Physiology of Venoarterial Extracorporeal Membrane Oxygenation” by Fresiello et al. in Perfusion
- 11 September 2024
- Published by SAGE Publications in Perfusion
- Vol. 40 (5) , 1297-1298
Letter re: Comments on the article “Physiology of Venoarterial Extracorporeal Membrane Oxygenation” by Fresiello et al. in Perfusion
- 30 July 2024
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 117 (11) , 650-651
Popping point: Unveiling the rare yet critical balloon rupture in transcatheter aortic valve implantation
- 30 July 2024
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 117 (11) , 650-651
Popping point: Unveiling the rare yet critical balloon rupture in transcatheter aortic valve implantation